ArticlePharmaceutics2023
β-Cyclodextrin Modified Hydrogels of Kappa-Carrageenan for Methotrexate Delivery.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Methotrexate-Cyclodextrin Systems: Molecular Recognition, Formulation Design, and Translational Perspectives.Current issues in molecular biology · 2026Review
- Dihydroquercetin in Weight Control: Systematic Review and Meta-Analysis of Preclinical Studies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Natural Regenerative Hydrogels for Wound Healing.Gels (Basel, Switzerland) · 2024Review
- Kappa-carrageenan and sodium alginate-based pH-responsive hydrogels for controlled release of methotrexate.Royal Society open science · 2024Article
- Cyclodextrin-grafted redox-responsive hydrogel mediated by disulfide bridges for regulated drug delivery.Designed monomers and polymers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
This work is aimed at developing a kappa-carrageenan (kCR) gel with increased methotrexate (MTX) content. β-Cyclodextrin (βCD), which is able to inclusion complex formation with MTX, has been used to increase the drug concentration in the hydrogel. The rheological behavior of the designed gels was investigated and the influence of MTX and βCD on the viscoelastic properties of kCR gel was studied in detail. The effect of βCD and its concentration on the MTX-releasing rate from the kCR gels was examined. The properties of kappa- and iota-carrageenans loaded with MTX were compared and the differences observed were explained in terms of different binding affinities of MTX to these polymers. The obtained gels provided desirable viscoelastic properties useful for topical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.